Biotechnology M&A update, 14–28 September 2026
A bi-weekly read on biotechnology: which of 74 covered names moved, what companies disclosed, and which deals crossed the record for September 14–28, 2026. Built for operators, acquirers and advisors tracking sector catalysts and M&A activity.
For information only. Not an appraisal or a fairness opinion.
The deeper read: Biotechnology Sector Outlook — September 2026
Key figures
- Sector median move
- -4.0%
- close-to-close, 74 covered names
- S&P 500 return
- +0.8%
- same two-week period
- Moderna (MRNA) move
- +34.5%
- following clinical disclosure
- ACADIA (ACAD) move
- -25.4%
- following clinical disclosure
Read the report
1 / 7 · HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › BIOTECHNOLOGY
Executive summary
Over September 14–28, 2026, 50 of 74 covered biotechnology names fell, with a sector median move of -4.0% against a +0.8% S&P 500 return, pointing to sector-specific rather than market-wide pressure. Moderna, Inc. (MRNA) gained +34.5% and ACADIA Pharmaceuticals Inc. (ACAD) fell -25.4%, both following clinical disclosures made inside the window. Four M&A transactions were recorded, none with a disclosed enterprise value, alongside PTC Therapeutics, Inc.'s (PTCT) completed acquisition of a Fabry gene therapy asset.
Key findings
- 50 of 74 covered names fell; sector median move was -4.0% versus +0.8% for the S&P 500
- Moderna (MRNA) rose +34.5% and ACADIA (ACAD) fell -25.4% on clinical disclosures
- Four M&A transactions were recorded, none with a disclosed enterprise value
- PTC Therapeutics (PTCT) closed its Fabry gene therapy acquisition in the period
What each page shows
The analyst’s walkthrough of the deck, page by page.
- 01BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE
HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › BIOTECHNOLOGY
Cover slide introducing the biotechnology bi-weekly industry events and M&A update for September 14–28, 2026.
This bi-weekly update covers biotechnology for September 14–28, 2026: what changed, who moved and most likely why, what transacted, and what it means. We'll walk through the market, the catalysts, and the deals in that order.
Everything on this page
BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › BIOTECHNOLOGY Readouts Sort the Sector as Buyers Keep Deals Small and Private This update covers movers, company announcements and M&A across biotechnology for the two-week period September 14–28, 2026. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Biotechnology Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1
- 02THE BI-WEEKLY BOTTOM LINE
Catalyst Calendars, Not the Market, Decided This Period
The period's headline is that company catalysts, not broad market direction, drove biotechnology share moves.
We covered 74 names this period on a close-to-close basis, and the sector median move was -4.0% while the S&P 500 returned +0.8% over the same window. That gap tells us the pressure was concentrated in biotechnology rather than reflecting a broader market pullback. The pages that follow break down which names moved, why, and what transacted, so you can separate sector noise from company-specific signal. So what: positioning in this sector needs to track individual catalysts, not the index.
Everything on this page
THE BI-WEEKLY BOTTOM LINE Catalyst Calendars, Not the Market, Decided This Period The two-week period in one page · 74 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Biotechnology Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 50 of 74 Covered Names Fell While the Index Held Up 50 of 74 covered names fell; the median move was -4.0%. The S&P 500 returned +0.8% over the same two-week period, so the pressure was sector-specific rather than market-wide. 2 Clinical Announcements Set Both Ends of the Range Moderna, Inc. (MRNA) gained +34.5% and ACADIA Pharmaceuticals Inc. (ACAD) fell -25.4%. In both cases shares moved following clinical disclosures the companies made inside the window. 3 Four Transactions Crossed the Record, None with a Disclosed Price Four transactions were recorded in the period against 40 in the trailing set, and PTC Therapeutics, Inc. (PTCT) confirmed completion of a gene therapy acquisition. None of the four carried a disclosed enterprise value. 4 The Period Fits the Two-Market View NeuraCap's standing view prices the sector on EV/Revenue, with a 4.7x sector median on CY2027E. This period, Premium-tier MRNA and Discount-tier ACAD moved in opposite directions on their own clinical news. +49.2% Best mover — DNA worst: PALI -26.8% · 24 up / 50 down of 74 covered -4.0% Sector median two-week return vs S&P 500 +0.8% 4 Transactions announced in the two-week period terms not fully disclosed 7 Company filings in the window 8-K events read for driver attribution
- 03PUBLIC MARKET MOVERS
Clinical News Set the Range; The Rest Moved on Positioning
Clinical disclosures explain the biggest individual share-price moves, while smaller moves reflect general positioning.
The sector median move was -4.0% against a +0.8% S&P 500 return, and we applied an ±11.5% sector-relative materiality bar to separate signal from noise. Moderna, Inc. (MRNA) gained +34.5% and ACADIA Pharmaceuticals Inc. (ACAD) fell -25.4%, in both cases following clinical disclosures made inside the window. Where we found no recorded driver for a move, we say so rather than guessing. So what: the largest moves are explainable by disclosed events, which is where diligence and monitoring should concentrate.
Everything on this page
PUBLIC MARKET MOVERS Clinical News Set the Range; The Rest Moved on Positioning Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median -4.0% · S&P 500 +0.8% · materiality bar ±11.5% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Biotechnology Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median -4.0% Ginkgo Bioworks Holdings, Inc. (DNA) +49.2% Shares moved following the September 16 announcement that the Ginkgo Datapoints offering entered a new agreement with a collaborative AI/ML drug discovery platform. Data-supply agreements with large discovery platforms are being priced as revenue quality, not only as platform optionality. COMPANY-SPECIFIC Moderna, Inc. (MRNA) +34.5% Shares moved following Moderna's September 21 announcement that Phase 3 adjuvant melanoma data for intismeran autogene was selected for an ESMO Presidential Symposium. A Premium-tier name can re-rate on the placement of a registrational readout, before the data itself is public. COMPANY-SPECIFIC Xeris Biopharma Holdings, Inc. (XERS) +29.9% No notable in-window news was identified that clearly explains the move. The +29.9% period return compares with a sector median move of -4.0%. Core-tier commercial names can gain ground even in a stretch where most covered names fell. UNEXPLAINED Palisade Bio, Inc. (PALI) -26.8% No notable in-window news was identified that clearly explains the move. The -26.8% period return compares with a sector median move of -4.0%. Single-asset clinical developers carry the widest two-week ranges in the covered set. UNEXPLAINED
- 04MAJOR NEWS & INDUSTRY CATALYSTS
What Companies Did: Rights Regained, a Label Eased, a Study Cleared
The slide lists the period's highest-impact company announcements, including rights regained, a label change, and a cleared study.
This period's most consequential company actions span a rights reversion, an eased label, and a study clearance, each linked back to its underlying filing or article. We read each event's likely significance, but the link to the primary source is always there for you to check yourself. These are the disclosures that, on the prior slide, we showed moving share prices in both directions. So what: these catalysts are the ones worth tracking into the next period for follow-through.
Everything on this page
MAJOR NEWS & INDUSTRY CATALYSTS What Companies Did: Rights Regained, a Label Eased, a Study Cleared The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Biotechnology Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 15 · 8-K · SEC EDGAR Ascendis Pharma regains exclusive TransCon rights in metabolic and cardiovascular disease With the collaboration ended, development, manufacturing and commercial economics for those products sit back with the company. That changes how the breadth of its platform is underwritten. A partnership ending can widen a platform's addressable value as easily as it narrows it. Sep 15 · 8-K · SEC EDGAR AstraZeneca's Non-Executive Chair bought ordinary shares in the company An open-market purchase by the chair is a direct read on how the board sees the company's position ahead of its next catalysts. Insider buying is one of the few non-clinical signals large-cap biopharma investors act on quickly. Sep 15 · 8-K · SEC EDGAR AstraZeneca's CFO acquired shares on the vesting of a 2021 performance share award Multi-year performance awards tie senior management outcomes to sustained delivery rather than to a single readout. Pay structured over several years is how diversified biopharma aligns leadership with pipeline replacement. Sep 15 · 8-K · SEC EDGAR LB Pharmaceuticals appointed a new Chief Medical Officer, effective September 14 A dedicated chief medical officer points to a company staffing up to run and defend a clinical programme through registrational work. Clinical leadership hires are an observable marker of where a development plan is heading next. Sep 14 · NEWS · PRNewsWire FDA approved reduced monitoring time for the first two doses of Amgen's IMDELLTRA Shorter monitoring supports administration in community settings, widening practical reach in extensive-stage small cell lung cancer without new clinical spend. Label changes that ease administration can move commercial reach as much as a new indication. Sep 14 · NEWS · GlobeNewsWire An independent DSMB recommended MediWound's EscharEx Phase III VALUE study continue unchanged A clean pre-specified safety review keeps a registrational study on its planned path and protects the catalyst calendar the equity is underwritten on. Uninterrupted registrational execution is a value driver in its own right.
- 05M&A & STRATEGIC ACTIVITY
PTC Closes Its Fabry Gene Therapy Buy as Four More Deals Cross the Record
Four M&A transactions were recorded in the period, headlined by PTC Therapeutics closing its Fabry gene therapy acquisition.
Four transactions were announced or closed in this period, and PTC Therapeutics, Inc. (PTCT) confirmed completion of its Fabry gene therapy acquisition. None of the four carried a disclosed enterprise value, which is consistent with how private-target consideration in this sector is typically reported. We treat deal rationale as a read of the recorded evidence, not as confirmed motive. So what: the record set keeps growing even without price disclosure, and that reference set is what should inform how you benchmark the next deal.
Everything on this page
M&A & STRATEGIC ACTIVITY PTC Closes Its Fabry Gene Therapy Buy as Four More Deals Cross the Record 4 transactions announced · September 14–28, 2026 · figures link to the filing Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Biotechnology Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 Sep 24 n/a Creative Medical Technology Holdings, Inc. Creative Medical Technology Holdings completed its acquisition of BioDefense, Inc. EV / LTM revenue n/a EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The record shows a completed purchase of a private target on September 24, consistent with smaller buyers adding assets rather than buying scale. HOW THE TARGET WAS VALUED No enterprise value was disclosed in the record for this transaction. Sep 23 n/a Arcturus Therapeutics Holdings Inc. Arcturus Therapeutics agreed to acquire myNEO EV / LTM revenue n/a EV / LTM EBITDA n/a WHY THE DEAL HAPPENED A platform developer buying a private target reads as adding capability rather than revenue; the record carries the agreement without terms. HOW THE TARGET WAS VALUED No enterprise value was disclosed in the record for this transaction. Sep 17 n/a Lisata Therapeutics, Inc. Lisata Therapeutics completed its acquisition of Marea Therapeutics EV / LTM revenue n/a EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The record shows a completed combination of clinical-stage developers on September 17, the structure the sector uses to pool cash runway and pipelines. HOW THE TARGET WAS VALUED No enterprise value was disclosed in the record for this transaction. +1 further transaction(s) recorded in the two-week period — full detail in the companion transaction record.
- 06WHAT IT MEANS
What the Period Changes for Operators, Acquirers and Advisors
The slide translates the period's events into observations for operators, acquirers and advisors.
For operators, the catalyst calendar did the pricing this period: placements, topline results, and label updates moved shares more than sentiment did. For acquirers, four more transactions entered the reference set, including PTC Therapeutics, Inc.'s (PTCT) completed purchase of a Fabry gene therapy asset. For advisors, the story is dispersion, not direction: 50 of 74 covered names fell with a -4.0% median move while the S&P 500 returned +0.8%. So what: each audience should lead with the disclosed event, not the index, when explaining this period's moves.
Everything on this page
WHAT IT MEANS What the Period Changes for Operators, Acquirers and Advisors The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Biotechnology Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / Revenue (CY2027E) median 4.7x 85 companies in the study 3 valuation tiers Standing thesis: Biotechnology Trades as Two Markets: Clinical-Stage Pipelines and Launched Biologics Revenue FOR OWNERS & OPERATORS The Catalyst Calendar Did the Pricing Companies traded on what they disclosed: registrational placements, topline results, regulatory label updates and conference presentations. FOR ACQUIRERS Four More Private Targets Enter the Reference Set The period added four transactions to the record, alongside PTC Therapeutics, Inc.'s (PTCT) completed purchase of a Fabry gene therapy asset. FOR ADVISORS Lead with the Readout, Not the Index The story is dispersion: 50 of 74 covered names fell; the median move was -4.0%, while the S&P 500 returned +0.8%.
- 07SOURCES & METHODOLOGY
Sources, Methodology and Important Notice
This slide explains the sources and methodology behind the update's figures and calibrated-language claims.
Every figure in this update links back to the filing, press release, or market data it was drawn from, through the period ending September 28, 2026. Driver attributions use calibrated language and reflect our read of the recorded evidence rather than asserted causation. Sources are admitted in a fixed reliability order, with video and social platforms excluded entirely. So what: you can trace every claim in this deck back to its primary source before acting on it.
Everything on this page
SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Biotechnology Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. 11 names below the floor were excluded from movers and statistics for this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T175750Z_553_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: sec.gov · prnewswire.com · globenewswire.com · newsfilecorp.com
Sources and methodology
This update covers Biotechnology over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 74 listed companies whose core business is Biotechnology under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: ACADIA Pharmaceuticals Inc. (ACAD), Alpha Cognition Inc. Common Stock (ACOG), ADMA Biologics, Inc. (ADMA), Alumis Inc. Common Stock (ALMS), Alvotech (ALVO), Amgen Inc. (AMGN), Annexon, Inc. (ANNX), Alto Neuroscience, Inc. (ANRO), Ardelyx, Inc. (ARDX), Arrowhead Pharmaceuticals, Inc. (ARWR), Ascendis Pharma A/S (ASND), Aurinia Pharmaceuticals Inc. (AUPH), ArriVent BioPharma, Inc. Common Stock (AVBP), AstraZeneca PLC (AZN), BridgeBio Pharma, Inc. (BBIO), BridgeBio Oncology Therapeutics Inc. (BBOT), BioAge Labs, Inc. (BIOA), Belite Bio, Inc (BLTE), Cibus, Inc. (CBUS), Celcuity Inc. (CELC), Climb Bio, Inc. (CLYM), COMPASS Pathways plc (CMPS), Cogent Biosciences, Inc. (COGT), CRISPR Therapeutics AG (CRSP), CytomX Therapeutics, Inc. (CTMX), Ginkgo Bioworks Holdings, Inc. (DNA), Denali Therapeutics Inc. (DNLI), Bright Minds Biosciences Inc. (DRUG), Emergent BioSolutions Inc. (EBS), Editas Medicine, Inc. (EDIT), Evolus, Inc. (EOLS), EyePoint Pharmaceuticals, Inc. (EYPT), Fulcrum Therapeutics, Inc. (FULC), Geron Corporation (GERN), Greenwich LifeSciences, Inc. (GLSI), Genelux Corporation (GNLX), HUTCHMED (China) Limited (HCM), IDEAYA Biosciences, Inc. (IDYA), Disc Medicine, Inc. (IRON), Keros Therapeutics, Inc. (KROS), LB Pharmaceuticals Inc Common Stock (LBRX), Lantheus Holdings, Inc. (LNTH), Maze Therapeutics, Inc. (MAZE), MediWound Ltd. (MDWD), Jyong Biotech Ltd. Ordinary Shares (MENS), MoonLake Immunotherapeutics (MLTX), MediciNova, Inc. (MNOV), Moderna, Inc. (MRNA), Nurix Therapeutics, Inc. (NRIX), Nuvation Bio Inc. (NUVB), OPKO Health, Inc. (OPK), ORIC Pharmaceuticals, Inc. (ORIC),
Window and company universe
This update covers Biotechnology over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 74 listed companies whose core business is Biotechnology under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: ACADIA Pharmaceuticals Inc. (ACAD), Alpha Cognition Inc. Common Stock (ACOG), ADMA Biologics, Inc. (ADMA), Alumis Inc. Common Stock (ALMS), Alvotech (ALVO), Amgen Inc. (AMGN), Annexon, Inc. (ANNX), Alto Neuroscience, Inc. (ANRO), Ardelyx, Inc. (ARDX), Arrowhead Pharmaceuticals, Inc. (ARWR), Ascendis Pharma A/S (ASND), Aurinia Pharmaceuticals Inc. (AUPH), ArriVent BioPharma, Inc. Common Stock (AVBP), AstraZeneca PLC (AZN), BridgeBio Pharma, Inc. (BBIO), BridgeBio Oncology Therapeutics Inc. (BBOT), BioAge Labs, Inc. (BIOA), Belite Bio, Inc (BLTE), Cibus, Inc. (CBUS), Celcuity Inc. (CELC), Climb Bio, Inc. (CLYM), COMPASS Pathways plc (CMPS), Cogent Biosciences, Inc. (COGT), CRISPR Therapeutics AG (CRSP), CytomX Therapeutics, Inc. (CTMX), Ginkgo Bioworks Holdings, Inc. (DNA), Denali Therapeutics Inc. (DNLI), Bright Minds Biosciences Inc. (DRUG), Emergent BioSolutions Inc. (EBS), Editas Medicine, Inc. (EDIT), Evolus, Inc. (EOLS), EyePoint Pharmaceuticals, Inc. (EYPT), Fulcrum Therapeutics, Inc. (FULC), Geron Corporation (GERN), Greenwich LifeSciences, Inc. (GLSI), Genelux Corporation (GNLX), HUTCHMED (China) Limited (HCM), IDEAYA Biosciences, Inc. (IDYA), Disc Medicine, Inc. (IRON), Keros Therapeutics, Inc. (KROS), LB Pharmaceuticals Inc Common Stock (LBRX), Lantheus Holdings, Inc. (LNTH), Maze Therapeutics, Inc. (MAZE), MediWound Ltd. (MDWD), Jyong Biotech Ltd. Ordinary Shares (MENS), MoonLake Immunotherapeutics (MLTX), MediciNova, Inc. (MNOV), Moderna, Inc. (MRNA), Nurix Therapeutics, Inc. (NRIX), Nuvation Bio Inc. (NUVB), OPKO Health, Inc. (OPK), ORIC Pharmaceuticals, Inc. (ORIC), Palisade Bio, Inc. (PALI), Vaxcyte, Inc. (PCVX), Prelude Therapeutics Incorporated (PRLD), PTC Therapeutics, Inc. (PTCT), Palvella Therapeutics, Inc. (PVLA), Arcus Biosciences, Inc. (RCUS), Regeneron Pharmaceuticals, Inc. (REGN), Atrium Therapeutics, Inc. (RNA). 11 names below the floor were excluded from the statistics: ALDX, CRDF, ELTX, FBIO, GANX, INO, KLRS, OKYO, ONCY, PLRX, PMVP.
How the moves and statistics are computed
Each company's period move is the change in closing price from the last close before the window to the last close inside it (close-to-close). The sector median is the median of those moves across the covered names; the index return is computed the same way for the S&P 500 over the same dates. The largest single-day move inside the window is shown for each mover. Movers are the largest gainers and losers by period move; the attribution cards prefer movers whose in-window record explains the move. Movers carry the valuation tier assigned in the standing sector study (the latest NeuraCap sector outlook) where that study rated them.
Events, news and how a move is attributed
Company events are the 8-K filings made inside the window; news items are publisher-sourced headlines for the window, admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron's and peers). Video and social platforms are never used. A move is linked to an event only when the event falls inside the window and only in calibrated language; where nothing in the record explains a move, the update says so rather than speculating. Every event links to its source.
Transactions in the window and the trailing record
Transactions are taken from SEC filings by announcement date; 4 were announced inside the window. The trailing record of 40 recorded transactions provides the reference multiples (EV over last-twelve-month revenue or EBITDA at announcement, as disclosed). A value whose own citation describes something other than the price paid is not shown as the deal value; transactions where the acquirer and the target are the same entity are treated as reorganisations and excluded.
Sources
Prices and index levels are market data through September 28, 2026; filings are the companies' SEC filings on EDGAR; press releases are the companies' own; other news items are from the established outlets named on each card; Treasury yields are published by the U.S. Department of the Treasury. Every figure and every event in the update links to its record.
Interpretation and important notice
'Why it matters', 'why the deal happened' and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, labelled as such. The update is informational: it is not investment advice, not a recommendation to buy or sell any security and not an offer of any kind.
Sources linked in the report
- +49.2% (businesswire.com)
- +34.5% (accessnewswire.com)
- +29.9% (defenseworld.net)
- -26.8% (globenewswire.com)
- Ascendis Pharma regains exclusive TransCon rights in metabolic and (sec.gov)
- AstraZeneca's Non-Executive Chair bought ordinary shares in the company (sec.gov)
- AstraZeneca's CFO acquired shares on the vesting of a 2021 performance (sec.gov)
- LB Pharmaceuticals appointed a new Chief Medical Officer, effective (sec.gov)
- FDA approved reduced monitoring time for the first two doses of Amgen's (prnewswire.com)
- An independent DSMB recommended MediWound's EscharEx Phase III VALUE study (globenewswire.com)
- n/a (sec.gov)
- n/a (sec.gov)
- sec.gov (sec.gov)
- globenewswire.com (globenewswire.com)
- newsfilecorp.com (newsfilecorp.com)
This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.
More coverage in Health Care
- Sector Outlook · 29 September 2026Biotechnology Sector Outlook — September 2026
- M&A Update · 29 September 2026Cardiovascular Devices M&A update, 14–28 September 2026
- Sector Outlook · 29 September 2026Cardiovascular Devices Sector Outlook — September 2026
- M&A Update · 29 September 2026Cell and Gene Therapies M&A update, 14–28 September 2026
Want this analysis for a company in Biotechnology?
Company valuation reports run the same method against a single business — public or private.
